COVID-19 trials registries data warehouse

 Return to trial list

Trial - IRCT20210901052358N3


Column Value
Trial registration number IRCT20210901052358N3
Full text link
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

First author
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Dr. Afshin Zarghi

Contact
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Mpajouhesh@sbmu.ac.ir

Registration date
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

2022-04-01

Recruitment status
Last imported at : Dec. 22, 2022, 12:23 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Completed

Study design
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

RCT

Allocation
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Randomized

Design
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Parallel

Masking
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Open label

Center
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

single-center

Study aim
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Treatment

Inclusion criteria
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Laboratory confirmation of COVID-19 virus by PCR Severe cases according to the World Health Organization guideline (peripheral blood oxygen saturation less than 90%, respiratory rate more than 30 per minute or symptoms of severe respiratory distress such as use of auxillary respiratory muscles or inability to complete sentences) Body mass index less than 40 kg per square meter No immunosuppressive diseases (primary, secondary and organ transplant defects, chemotherapy or radiotherapy) Patient willingness to participate in the study Non-pregnant and non-lactating women Serum CRP level greater than 75 mg / L Do not receive immunomodulatory drugs for 6 months before No history of severe hypersensitivity to tosilizumab and tofacitinib and similar compounds No history of active gastric ulcer, active diverticulitis and other gastrointestinal diseases with risk of intestinal perforation No active hepatitis or tuberculosis or a bacterial or fungal or viral infection other than COVID-19 No history of chronic kidney disease (GFR less than 30 ml / min)

Exclusion criteria
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Severe drug allergy and anaphylactic shock Death in the first 24 hours of hospitalization Increase in liver enzymes to more than 10 times the normal upper limit Decrease in neutrophil count to less than 500 cells per microliter Decrease in platelet count to less than 50,000 cells per microliter GFR less than 30 ml per minute

Number of arms
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

2

Funding
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Shahid Beheshti University of Medical Sciences

Inclusion age min
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

18

Inclusion age max
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

100

Countries
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Iran

Type of patients
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Severe disease at enrollment

Severity scale
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

6: Severe disease at enrollment

Total sample size
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

60

primary outcome
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Mortality Admission to the intensive care unit Use of mechanical ventilation Hospitalization length

Notes
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Phase
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Not reported

Arms
Last imported at : April 1, 2022, 3:41 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)

[{"arm_notes": "", "treatment_id": 1299, "treatment_name": "Tocilizumab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1300, "treatment_name": "Tofacitinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}]